iiinova — where your digital self keeps evolving

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 06/10/2026

New research online! Bassel Barhoum and colleagues conducted a 5-year longitudinal study to understand the changes of vaccination status, hesitance and knowledge in people with #MultipleSclerosis: journals.sagepub.com/doi/full/10....

021

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 07/10/2026

New Review online! Closed-loop spinal cord stimulation as a dynamic therapy for parkinsonian orthostatic hypotension: journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 08/10/2026

Get ready for #ESMO26 by revisiting the evolving treatment landscape of #SCLC with this review published on #TAMO in 2025. From current standards to DLL3-targeted therapies, #ADCs and emerging biomarkers. #Lungcancer 🔗 buff.ly/B2U9VpQ @Roya_Behrouzi @fblackhall

011

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 08/10/2026

How safe and effective is #telitacicept as add-on therapy for myasthenic crisis? Check out this analysis of a retrospective cohort here: journals.sagepub.com/doi/full/10.... #MyastheniaGravis

011

Reposted by Jen L, PhD

Natural Product Communications @naturalproductcomm.bsky.social · 12/10/2026

Top Read Papers on Natural Product Communications - October 2026 1. Physicochemical and Biological Characterisation of a Crystalline Wood Exudate (“Wood Snow”) From the Endemic Conifer Cupressus tonkinensis journals.sagepub.com/doi/10.1177/...

021

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 12/10/2026

🆕 New Review online! 🆕 ⚠️ What are the contraindications to endovascular treatment in acute ischemic #stroke? 📰 Apostolos Safouris and colleagues review the evidence: journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 13/10/2026

Candida tropicalis spondylodiscitis: a rare, indolent infection that can be easily missed. Persistent fever and elevated β-D-glucan should prompt consideration of an occult fungal focus. journals.sagepub.com/doi/full/10....

journals.sagepub.com

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

011

Reposted by Jen L, PhD

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 13/10/2026

Often mistaken for TB, Histoplasma can affect immunocompetent and immunocompromised patients. This review highlights critical diagnostic gaps, and proposes a pragmatic testing pathway while outlining priorities for future research. journals.sagepub.com/doi/full/10....

journals.sagepub.com

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

011

Reposted by Jen L, PhD

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 13/10/2026

Pseudomonas aeruginosa UTIs in Palestine: In a 190-patient cohort, mortality was 11.6%. Immunocompromised status & meropenem resistance were independent predictors of mortality, highlighting early risk recognition and appropriate antimicrobial therapy. journals.sagepub.com/doi/full/10....

journals.sagepub.com

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

011

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 03/10/2026

What are the treatment patterns & access and burden of #MOGAD in China? Check out this nationwide cross-sectional study by Yue Yu & colleagues: journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 04/10/2026

What is the clinical efficacy and safety of #telitacicept in patients with primary central nervous system #vasculitis? Jiangyi Lyu and colleagues report real-world data: journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 05/10/2026

What is the effect of #MOGAD on brain volume & networks in pediatric patients? Shangru Li and colleagues investigated: journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 05/10/2026

Online on #TAMO Lymphocyte recovery after breast RT may take years. In 203 pts from the phase III CHN HYPOBREAST trial, HFRT was associated with less ≥G2 lymphopenia vs CFRT (6.5% vs 24.5%) and earlier recovery to baseline. #BreastCancer #RadOnc buff.ly/gW1OmN9

011

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 28/09/2026

New online! Does BMI correlate with cognitive function, disability or quality of life in patients with #MultipleSclerosis? Aliza Bitton Ben-Zacharia & colleagues investigated: journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 28/09/2026

🩸 How can a lipid–endothelial #signature stratify patients with #HCC? Luxi Yang et al. explore this through an integrated multi-omics approach, linking a six-gene signature with prognosis and immune-excluded features in HCC. 🔗 buff.ly/YnGZpEo

012

Reposted by Jen L, PhD

Therapeutic Advances in Respiratory Disease @tarespirdis.bsky.social · 29/09/2026

Takayasu's arteritis is rare and balloon angioplasty can help improve survival. Read this cohort study to understand more about how this advanced center manages their patient population. journals.sagepub.com/doi/10.1177/.... @ild-ipfdoc.bsky.social

032

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 29/09/2026

What's the patient satisfaction of subcutaneous #natalizumab in patients with relapsing-remitting #MultipleSclerosis? Chiara Zecca and colleagues report the results from the real-world, multicenter Swiss SATYSFACTION study: journals.sagepub.com/doi/full/10....

021

Reposted by Jen L, PhD

Natural Product Communications @naturalproductcomm.bsky.social · 29/09/2026

Top Read Papers on Natural Product Communications - September 2026 8. Traditional Antimalarial Medicinal Plants of Sudan: A Review of Ethnopharmacology, Antiplasmodial Extracts and Phytochemicals, Toxicology, and Future Prospects journals.sagepub.com/doi/10.1177/...

022

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 30/09/2026

More on subcutaneous #natalizumab for #MultipleSclerosis: Final results from the SISTER study journals.sagepub.com/doi/full/10....

012

Reposted by Jen L, PhD

Natural Product Communications @naturalproductcomm.bsky.social · 01/10/2026

💡 Editorial Review Board Member of the month - Oct 2026 We interviewed Dr Ling Li (Mississippi State University, USA) thismonth. Her research explores plant metabolism and environmental responses using genomic, molecular, and gene-editing approaches. Read more: journals.sagepub.com/page/npx/erb...

021

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 01/10/2026

What are the risk factors for depressive symptoms in #seizure disorders? Find out more in this new article by Jon Davis Perkins & colleagues: #epilepsy #depression journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 01/10/2026

What is the efficacy & safety of the interleukin-6 receptor inhibitors #tocilizumab and #satralizumab in #MOGAD? Aasim Ali & colleagues conducted a #SystematicReview and #MetaAnalysis to summarize the evidence: journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 01/10/2026

On #TAMO in 2025 How can AR-targeted therapy move beyond resistance in #prostate cancer? Emerging strategies (i.e. CYP11A1 inhibition/AR degraders/EZH2 inhibitors) are explored in this comprehensive review. @alicebernardt journals.sagepub.com/doi/10.1177/...

011

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 02/10/2026

New Review online! Charlotte A. René and Robin J Parks provide an update on biology, pathogenesis and therapeutic advances in spinal muscular atrophy: journals.sagepub.com/doi/full/10....

021

Jen L, PhD @drjkyl.bsky.social · 02/10/2026

A pilot phase IIa randomized, placebo-controlled, double-blind trial of intravenous human pluripotent adipose-derived stem cells (PASCs) in Parkinson’s disease: The REPOSE study @celltransplant1992.bsky.social @journals.sagepub.com journals.sagepub.com/doi/10.1177/... #neurodegenerativedisease

000

Jen L, PhD @drjkyl.bsky.social · 02/10/2026

Sensitivity and specificity of FDG-PET in detecting abdominopelvic disease in desmoplastic small round cell tumor Rare Tumors @journals.sagepub.com journals.sagepub.com/doi/10.1177/... #sarcoma #medicalimaging #cancer #oncology #openaccess

000

Jen L, PhD @drjkyl.bsky.social · 02/10/2026

Extragastrointestinal stromal tumor involving the adrenal region: A rare case report Rare Tumors @journals.sagepub.com journals.sagepub.com/doi/10.1177/... #GISTs #cancer #oncology #openaccess

000

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 22/09/2026

New online! 💉 What is the real-life effectiveness of #onabotulinumtoxinA for #migraine? Find out more in this cohort of 479 patients from 12 Polish specialized headache centers: journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Natural Product Communications @naturalproductcomm.bsky.social · 23/09/2026

Top Read Papers on Natural Product Communications - September 2026 6. In Vitro Antibacterial Activity of Crude Leaf Extracts of Pentas Schimperiana journals.sagepub.com/doi/10.1177/...

021

Reposted by Jen L, PhD

Natural Product Communications @naturalproductcomm.bsky.social · 23/09/2026

Top Read Papers on Natural Product Communications - September 2026 7. Phytochemical Evaluation and HPTLC Fingerprinting for the Standardization of Pachai Pakku Thailam, a Traditional Siddha Herbal Formulation for Non-Healing Ulcers journals.sagepub.com/doi/10.1177/...

031

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 23/09/2026

New online! 📰 Advances and challenges of the clinical implementation of the 2024 McDonald criteria for #MultipleSclerosis: Practical considerations and consensus recommendations from German experts journals.sagepub.com/doi/full/10....

012

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 23/09/2026

Evidence in NUT #carcinoma remains limited. This retrospective series of 25 H&N offers interesting insights into histologic differentiation and prognosis, including the adverse prognostic association of neuroendocrine differentiation. buff.ly/Evhy0A9

011

Reposted by Jen L, PhD

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 24/09/2026

Mining may be an important occupational risk factor for TB. In a case-control study from Ethiopia (n=735), miners had >3× higher odds of active pulmonary TB (AOR 3.51, 95% CI 1.89–6.50). journals.sagepub.com/doi/full/10....

journals.sagepub.com

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

011

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 25/09/2026

New randomized controlled trial online! What is the effect of adding #atorvastatin or #rosuvastatin to #clopidogrel on preventing platelet activation and vascular events prevention in patients with acute large-vessel minor #stroke or TIA? journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 25/09/2026

TB stigma remains a major barrier to TB control. In this study of 385 patients in Napak district, Uganda, 43.1% reported high perceived stigma. Poor TB knowledge, inadequate social support, and secondary education were associated with higher stigma journals.sagepub.com/doi/full/10....

journals.sagepub.com

Prevalence of perceived stigma and associated factors among patients with tuberculosis in Napak district, Karamoja region, Uganda: A cross-sectional study - Victor Lomonyang, Saadick Mugerwa Ssentongo...

Background Tuberculosis (TB) remains a leading cause of infectious disease mortality globally. Stigma is a critical social determinant that undermines health-se...

011

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 25/09/2026

On #TAMO in 2025 🤰 Fertility preservation is a key component of care for young patients with #breast #cancer. Interesting evidence in this RW cohort where 54% underwent cryopreservation. More details here: journals.sagepub.com/doi/full/10.... @matteolambe

011

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 13/09/2026

A new Letter to the Editor online: Evolving #MultipleSclerosis criteria and the interpretation of research journals.sagepub.com/doi/full/10....

022

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 14/09/2026

What are the risk factors for relapse and poor outcomes in anti-LGI1 #encephalitis? Find out more here: journals.sagepub.com/doi/full/10....

021

Reposted by Jen L, PhD

Natural Product Communications @naturalproductcomm.bsky.social · 14/09/2026

Top Read Papers on Natural Product Communications - September 2026 5. Anticancer Mechanism of Thalictrum punduanum Root Extract Against Breast and Colorectal Cancer: A Network Pharmacology and Molecular Docking Simulation Insights journals.sagepub.com/doi/10.1177/...

021

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 15/09/2026

New Systematic Review online! What is the safety and cognitive efficacy of compounds derived from marine organisms in #Alzheimer's disease? journals.sagepub.com/doi/full/10....

011

Reposted by Jen L, PhD

Therapeutic Advances in Respiratory Disease @tarespirdis.bsky.social · 15/09/2026

Congratulations to our Editorial Review Board member Maria Koulopoulou on presenting at #ERSCongress2026, with work focused on developing a competency framework for specialist ILD healthcare practitioners. #ILD #RespiratoryCare #RespiratoryResearch

011

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 15/09/2026

Management of #testicular #cancer still diverges from guidelines. Adj treatment remains common in stage I disease despite surveillance-based recommendations, while repeat imaging in stage IIA is inconsistently used. More details 👉️ buff.ly/3oeKQLu #oncology #realworld

011

Reposted by Jen L, PhD

Natural Product Communications @naturalproductcomm.bsky.social · 16/09/2026

💡 Editorial Review Board Member of the month - September 2026 This month, we interviewed Prof. Gunawan Indrayanto, an independent consultant who specializes in chemical, pharmaceutical, herbal analysis, metabolomics, and analytical method validation. Read more: journals.sagepub.com/page/npx/erb...

021